Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

(2022) Michael J. Koren et al.   NATURE MEDICINE

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

(2021) Sander F. Garrelfs et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

(2021) Gregory G. Schwartz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

(2020) Vera A. Bittner et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

(2020) Sotirios Tsimikas et al.   NEW ENGLAND JOURNAL OF MEDICINE

The dedicated “Lp(a) clinic”: A concept whose time has arrived?

(2020) Sotirios Tsimikas et al.   ATHEROSCLEROSIS

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

(2020) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

(2020) Manisha Balwani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial

(2020) Michael Szarek et al.   EUROPEAN HEART JOURNAL

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates

(2020) Christopher R Brown et al.   NUCLEIC ACIDS RESEARCH

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

(2019) Federica Fogacci et al.   DRUGS

Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes

(2019) Claudia Lamina et al.   JAMA Cardiology

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials

(2019) Kausik K. Ray et al.   ATHEROSCLEROSIS

Elevated Lipoprotein(a) and Risk of Ischemic Stroke

(2019) Anne Langsted et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention

(2019) Christian M. Madsen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate

(2018) Karam M. Kostner et al.   ATHEROSCLEROSIS

RNA-Targeted Therapeutics

(2018) Stanley T. Crooke et al.   Cell Metabolism

Advances in lipid-lowering therapy through gene-silencing technologies

(2018) Børge G. Nordestgaard et al.   Nature Reviews Cardiology

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

(2018) Aaron D. Springer et al.   Nucleic Acid Therapeutics

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

(2018) Stephen Burgess et al.   JAMA Cardiology

RNA Therapeutics in Cardiovascular Precision Medicine

(2018) Ageliki Laina et al.   Frontiers in Physiology

High lipoprotein(a) and high risk of mortality

(2018) Anne Langsted et al.   EUROPEAN HEART JOURNAL

A Test in Context: Lipoprotein(a)

(2017) Sotirios Tsimikas   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United StatesHighlights

(2016) Steve Varvel et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Structure, function, and genetics of lipoprotein (a)

(2016) Konrad Schmidt et al.   JOURNAL OF LIPID RESEARCH

Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels

(2016) Connor A. Emdin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population

(2016) Pia R. Kamstrup et al.   JACC-Heart Failure

Current therapies for lowering lipoprotein (a)

(2015) Julian C. van Capelleveen et al.   JOURNAL OF LIPID RESEARCH

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans

(2015) Mark J. Graham et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis: A Prospective Mendelian Randomization Study and Replication in a Case-Control Cohort

(2014) B. J. Arsenault et al.   Circulation-Cardiovascular Genetics

Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population

(2014) Elaine T. Lim et al.   PLoS Genetics

Lipoprotein(a): resurrected by genetics

(2013) F. Kronenberg et al.   JOURNAL OF INTERNAL MEDICINE

Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population

(2013) Pia R. Kamstrup et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mechanisms of Lipoprotein(a) Pathogenicity

(2012) J. David Spence et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease

(2012) Deepti Gurdasani et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction

(2009) Pia R. Kamstrup   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population

(2007) Pia R. Kamstrup et al.   CIRCULATION